Glioblastoma Multiforme (GBM) Pipeline Analysis (2024)

Recent Breakthroughs in Glioblastoma Multiforme Pipeline:

• In July, 2024: Universitätsmedizin Mannheim announced that INTRAGO II is a multicentric, prospective, randomized, two-arm, open-label phase III clinical trial designed to evaluate whether adding intraoperative radiotherapy (IORT) to standard radiochemotherapy can enhance median progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM).
• In July,2024: CarThera announced that the brain is shielded from toxic and inflammatory molecules by the blood-brain barrier (BBB), a physical barrier situated in the walls of blood vessels. This barrier not only protects the brain but also restricts the passage of therapeutic molecules from the bloodstream into the brain. Consequently, developing effective treatments for glioblastoma is challenging because the BBB prevents most drugs administered via the bloodstream from reaching the brain tissue where the tumor resides.
• In June,2024: CNS Pharmaceuticals, Inc. announced that Berubicin is among the first anthracyclines capable of crossing the blood-brain barrier and overcoming drug resistance, as it is not a substrate for multi-drug resistant or breast cancer resistant transporters. A Phase 1 clinical trial involving patients with primary CNS malignancies showed promising results, including a durable response (one patient surviving for over 13 years) and stable disease in heavily pretreated individuals. Consequently, this Phase 2 study aims to further assess Berubicin's efficacy in patients with recurrent glioblastoma multiforme (rGBM) following standard care treatment.
• In June,2024: Philogen S.p.A. announces the trials aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence

 Learn about groundbreaking developments like the INTRAGO II trial, advancements in overcoming the blood-brain barrier, and innovative treatments like Berubicin and L19TNF in Glioblastoma Multiforme Pipeline Insight

Glioblastoma Multiforme (GBM) remains one of the most aggressive and challenging forms of brain cancer, with a high demand for innovative treatments. According to DelveInsight's assessment, over 195 key pharma and biotech companies are currently working on more than 210 pipeline drugs targeting GBM. These efforts span various routes of administration (ROA), mechanisms of action (MOA), and molecule types, with several therapies in advanced stages of clinical development expected to launch in the coming years.

Key Highlights from the Delveinsight’s “Glioblastoma Multiforme (GBM) Pipeline Analysis (2024)” Report:

• Key companies in the Glioblastoma Multiforme include: Oncotelic Therapeutics, Ascletis, AstraZeneca, Bayer, BioMimetix, BioNTech, Karyopharm Therapeutics, Celgene Corporation, Chimerix
• Emerging therapies for the market include: Afatinib (Boehringer Ingelheim), Avastin (Genentech), AZD1390 (AstraZeneca), Crenolanib (AROG Pharmaceuticals), CYNK 001 (Celularity), DCVax-L (Northwest Pharmaceuticals), Durvalumab (MedImmune), G207 (Treovir), ITI-1000 (Immunomic Therapeutics), LAM561 (Laminar Pharmaceuticals), MDNA55 (Medicenna Therapeutics), Ofranergene obadenovec (VBL Therapeutics), ONC201 (Chimerix) and others...

Comprehensive Glioblastoma Multiforme Pipeline Insights

DelveInsight's "Glioblastoma Multiforme Pipeline Insight, 2023" report offers a detailed analysis of the ongoing clinical development activities and future growth prospects in the GBM therapeutics market. The report provides insights into the mechanisms of action, types, stages, routes of administration, molecule types, clinical studies, inactive pipeline products, and NDA approvals, if any. It also covers the commercial and clinical activities of the pipeline products, from pre-clinical phases to market stages, highlighting collaborations, licensing, mergers and acquisitions (M&A), funding, designations, and other product-related developments.

Key Insights

1. Detailed Company Analysis: The report highlights key companies developing GBM therapies, segmented into early-stage, mid-stage, and late-stage of development.
2. Therapeutic Candidates Evaluation: It evaluates therapeutic candidates based on their stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
3. Collaborations and Licensing: Detailed analysis of collaborations, licensing agreements, and financing details for future advancements in the GBM treatment market.

Current Glioblastoma Multiforme Treatment Landscape

Treatment for GBM typically involves a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Surgery is often a critical component, aimed at achieving maximum safe resection—removing as much of the tumor as possible while preserving brain function. Following surgery, residual cancer cells are targeted with chemotherapy or radiation therapy. The first-line treatment usually includes Temozolomide combined with radiation therapy, while second-line treatments may involve Bevacizumab monotherapy, Bevacizumab combination therapy, and other systemic therapies.

Leading Companies in Glioblastoma Multiforme Therapeutics

The GBM therapeutics market features numerous prominent companies, each contributing to the development of innovative treatments:

• Oncotelic Therapeutics
• Ascletis
• AstraZeneca
• Bayer
• BioMimetix
• BioNTech
• Karyopharm Therapeutics
• Celgene Corporation
• Chimerix

Emerging and Marketed Therapies in Glioblastoma Multiforme

The report covers a broad range of emerging and marketed GBM therapies:

• Afatinib (Boehringer Ingelheim)
• AV-GBM-1 (Aivita Biomedical)
• Avastin (Genentech)
• AZD1390 (AstraZeneca)
• Crenolanib (AROG Pharmaceuticals)
• CYNK 001 (Celularity)
• DCVax-L (Northwest Pharmaceuticals)
• Durvalumab (MedImmune)
• G207 (Treovir)
• ITI-1000 (Immunomic Therapeutics)
• LAM561 (Laminar Pharmaceuticals)
• MDNA55 (Medicenna Therapeutics)
• Ofranergene obadenovec (VBL Therapeutics)
• ONC201 (Chimerix)
• Onfekafuspalfa (Philogen)
• Paxalisib (Kazia Therapeutics)
• PVSRIPO (Istari Oncology)
• Regorafenib (Bayer Healthcare)
• Selinexor (Karyopharm Therapeutics)
• Tasadenoturev (DNAtrix)
• Temodar/Temodal (Merck)
• Trabedersen (Oncotelic Therapeutics)
• Trans Sodium Crocetinate (Diffusion Pharmaceuticals)
• TVB2640 (Ascletis Pharma)
• VAL-083 (Kintara Therapeutics)
• VBI-1901 (VBI Vaccines)
• YTX7739 (Yumanity Therapeutics)

Therapeutic Development Stages

The Glioblastoma Multiforme pipeline report categorizes emerging therapies into various stages of clinical development, including:

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Discover detailed analyses of companies making significant strides in the Glioblastoma Multiforme treatment market

Route of Administration and Molecule Types

The therapeutic assessment includes an analysis of pipeline drugs by their route of administration and molecule types. Products are categorized under various ROAs such as oral, intravenous, subcutaneous, parenteral, and topical. Molecule types include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapies.

Conclusion

Glioblastoma Multiforme remains a critical area of focus within oncology, with extensive research and development efforts underway to provide innovative and effective treatments. DelveInsight's comprehensive pipeline analysis offers valuable insights into the current and future landscape of GBM therapeutics, highlighting the significant contributions of leading pharma and biotech companies in advancing the fight against this aggressive cancer.

For more detailed insights and to stay updated on the latest developments in GBM therapeutics, visit DelveInsight's report store.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.